.... Screening for cervical cancer is very effective at controlling the disease, but the costs for the 32 million women involved in EU screening programmes costs approximately €960 million per year. Tumour Trace Limited have developed OMIS, an innovative cancer screening methodology and device which offers a reduction of 75% costs for laboratories and accuracy of over 95%. This technology uses Opto-M ...